A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Completed · Phase 1

Conditions studied: Malignant Neoplasm

In brief

The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.

Key facts

Study ID

NCT06894771

Run by

Merck Sharp & Dohme LLC

People needed

5

Starts

2025-04-23

Expected to finish

2025-12-08

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Has histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report who have experienced disease progression on or after prior anti-cancer treatments, or been intolerant to, or refused all treatment known to confer clinical benefit
• Has head and neck squamous cell carcinoma (HNSCC), melanoma (cutaneous), non-small cell lung cancer (NSCLC), cervical cancer, triple negative breast cancer (TNBC), urothelial carcinoma (UC), or renal cell carcinoma (RCC; clear cell, papillary)
• If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART)
• Has normal cardiac function

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• If HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• Has known additional malignancy that is progressing or has required active treatment within the past 2 years
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
• Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids
• Has current pneumonitis/interstitial lung disease
• Has active infection requiring systemic therapy
• Has known history of Hepatitis B (defined as Hepatitis B surface antigen reactive) or known active Hepatitis C virus infection
• Has had an allogeneic tissue/solid organ transplant in the last 5 years

Where it is running

• John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301) — Hackensack, New Jersey, United States
• NEXT Oncology ( Site 0300) — San Antonio, Texas, United States
• Princess Margaret Cancer Center ( Site 0101) — Toronto, Ontario, Canada
• Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102) — Québec, Quebec, Canada
• Rambam Health Care Campus ( Site 0201) — Haifa, Israel
• Rabin Medical Center ( Site 0202) — Petah Tikva, Israel
• Sheba Medical Center ( Site 0200) — Ramat Gan, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.